1.Goorhuis, A, et al. Emergence of Clostridium difficile infection due to a new hypervirulent strain, polymerase chain reaction ribotype 078. Clinical Infectious Diseases 2008; 47: 1162–1170.
2.Loo, VG, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. New England Journal of Medicine 2005; 353: 2442–2449.
3.Warny, M, et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 2005; 366: 1079–1084.
4.Lin, YC, et al. Antimicrobial susceptibilities and molecular epidemiology of clinical isolates of Clostridium difficile in Taiwan. Antimicrobial Agents and Chemotherapy 2011; 55: 1701–1705.
5.Chung, CH, et al. Clostridium difficile infection at a medical center in southern Taiwan: incidence, clinical features and prognosis. Journal of Microbiology Immunolology and Infection 2010; 43: 119–125.
6.Hsu, MS, et al. Prevalence and clinical features of Clostridium difficile-associated diarrhea in a tertiary hospital in northern Taiwan. Journal of Microbiology Immunolology and Infection 2006; 39: 242–248.
7.McFarland, LV, Surawicz, CM, Stamm, WE. Risk factors for Clostridium difficile carriage and C. difficile-associated diarrhea in a cohort of hospitalized patients. Journal of Infectious Diseases 1990; 162: 678–684.
8.McFarland, LV, et al. Nosocomial acquisition of Clostridium difficile infection. New England Journal of Medicine 1989; 320: 204–210.
9.Cohen, SH, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infection Control and Hospital Epidemiology 2010; 31: 431–455.
10.Baron, EJ, et al. Classification and identification of bacteria, In Murray, PR, Baron, EJ, Pfaller, MA, et al. , eds. Manual of Clinical Microbiology, 6th edn.ASM Press, Washington, DC, 1995, pp. 249–264.
11.Persson, S, Torpdahl, M, Olsen, KE. New multiplex PCR method for the detection of Clostridium difficile toxin A (tcdA) and toxin B (tcdB) and the binary toxin (cdtA/cdtB) genes applied to a Danish strain collection. Clinical Microbiology and Infection 2008; 14: 1057–1064.
12.Dridi, L, et al. gyrA and gyrB mutations are implicated in cross-resistance to Ciprofloxacin and moxifloxacin in Clostridium difficile. Antimicrobial Agents and Chemotherapy 2002; 46: 3418–3421.
13.Pasanen, T, et al. Comparison of repetitive extragenic palindromic sequence-based PCR with PCR ribotyping and pulsed-field gel electrophoresis in studying the clonality of Clostridium difficile. Clinical Microbiology and Infection 2011; 17: 166–175.
14.Lee, NY, et al. Clostridium difficile bacteremia, Taiwan. Emerging Infectious Diseases 2010; 16: 1204–1210.
15.Stubbs, SL, et al. PCR targeted to the 16S-23S rRNA gene intergenic spacer region of Clostridium difficile and construction of a library consisting of 116 different PCR ribotypes. Journal of Clinical Microbiology 1999; 37: 461–463.
16.Hundsberger, T, et al. Transcription analysis of the genes tcdA-E of the pathogenicity locus of Clostridium difficile. European Journal of Biochemistry 1997; 244: 735–742.
17.Matamouros, S, England, P, Dupuy, B. Clostridium difficile toxin expression is inhibited by the novel regulator TcdC. Molecular Microbiology 2007; 64: 1274–1288.
18.Yang, YX, Metz, DC. Safety of proton pump inhibitor exposure. Gastroenterology 2010; 139: 1115–1127.
19.McDonald, LC, et al. An epidemic, toxin gene-variant strain of Clostridium difficile. New England Journal of Medicine 2005; 353: 2433–2441.
20.McCarthy, DM. Adverse effects of proton pump inhibitor drugs: clues and conclusions. Current Opinion of Gastroenterology 2010; 26: 624–631.
21.Pepin, J, et al. Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clinical Infectious Diseases 2005; 40: 1591–1597.
22.Shah, S, et al. Gastric acid suppression does not promote clostridial diarrhoea in the elderly. Quarteryly Journal of Medicine 2000; 93: 175–181.
23.Dial, S, et al. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. Journal of American Medical Association 2005; 294: 2989–2995.
24.Dial, S, et al. Proton pump inhibitor use and risk of community-acquired Clostridium difficile-associated disease defined by prescription for oral vancomycin therapy. Canadian Medical Association Journal 2006; 175: 745–748.
25.Cunningham, R, et al. Proton pump inhibitors as a risk factor for Clostridium difficile diarrhoea. Journal of Hospital Infection 2003; 54: 243–245.
26.Kazakova, SV, et al. A hospital outbreak of diarrhea due to an emerging epidemic strain of Clostridium difficile. Archives of Internal Medicine 2006; 166: 2518–2524.
27.Leonard, J, Marshall, JK, Moayyedi, P. Systematic review of the risk of enteric infection in patients taking acid suppression. American Journal of Gastroenterology 2007; 102: 2047–2056.
28.Paredes-Sabja, D, et al. Germination of spores of Clostridium difficile strains, including isolates from a hospital outbreak of Clostridium difficile-associated disease (CDAD). Microbiology 2008; 154: 2241–2250.
29.Howell, MD, et al. Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection. Archives of Internal Medicine 2010; 170: 784–790.